<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">8907828</journal-id>
<journal-id journal-id-type="pubmed-jr-id">20554</journal-id>
<journal-id journal-id-type="nlm-ta">J Psychopharmacol</journal-id>
<journal-id journal-id-type="iso-abbrev">J. Psychopharmacol. (Oxford)</journal-id>
<journal-title-group>
<journal-title>Journal of psychopharmacology (Oxford, England)</journal-title>
</journal-title-group>
<issn pub-type="ppub">0269-8811</issn>
<issn pub-type="epub">1461-7285</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">29237331</article-id>
<article-id pub-id-type="pmc">5805024</article-id>
<article-id pub-id-type="doi">10.1177/0269881117741766</article-id>
<article-id pub-id-type="manuscript">EMS75921</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Autism Spectrum Disorder: consensus guidelines on assessment, treatment and research from the British Association for Psychopharmacology</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Howes</surname>
<given-names>Oliver D</given-names>
</name>
<degrees>MRCPsych, PhD</degrees>
<aff id="A1">MRC London Institute of Medical Sciences, London, UK and Institute of Psychiatry, Psychology &amp; Neuroscience, King’s College London</aff>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Rogdaki</surname>
<given-names>Maria</given-names>
<prefix>Dr</prefix>
</name>
<degrees>MBBS</degrees>
<aff id="A2">MRC London Institute of Medical Sciences, London, UK</aff>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Findon</surname>
<given-names>James L.</given-names>
</name>
<degrees>MSc</degrees>
<aff id="A3">Sackler Institute for Translational Neurodevelopment, Department of Forensic and Neurodevelopmental Sciences, Institute of Psychiatry, Psychology &amp; Neuroscience, King’s College London</aff>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Wichers</surname>
<given-names>Robert H.</given-names>
<prefix>Dr</prefix>
</name>
<degrees>BSc</degrees>
<aff id="A4">Sackler Institute for Translational Neurodevelopment, Department of Forensic and Neurodevelopmental Sciences, Institute of Psychiatry, Psychology &amp; Neuroscience, King’s College London</aff>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Charman</surname>
<given-names>Tony</given-names>
</name>
<degrees>PhD</degrees>
<aff id="A5">Department Psychology, Institute of Psychiatry, Psychology &amp; Neuroscience, King’s College London</aff>
</contrib>
<contrib contrib-type="author">
<name>
<surname>King</surname>
<given-names>Bryan H.</given-names>
</name>
<degrees>MD, MBA</degrees>
<aff id="A6">Department of Psychiatry, Weill Institute for Neurosciences, University of California at San Francisco, USA</aff>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Loth</surname>
<given-names>Eva</given-names>
</name>
<degrees>PhD</degrees>
<aff id="A7">Sackler Institute for Translational Neurodevelopment and Department of Forensic and Neurodevelopmental Sciences, Institute of Psychiatry, Psychology &amp; Neuroscience, King’s College London</aff>
</contrib>
<contrib contrib-type="author">
<name>
<surname>McAlonan</surname>
<given-names>Gráinne M.</given-names>
<prefix>Dr</prefix>
</name>
<aff id="A8">The Sackler Centre and Forensic and Neurodevelopmental Science Behavioural and Developmental Psychiatry, Clinical Academic Group and NIHR-BRC for Mental Health at South London and Maudsley NHS Foundation Trust</aff>
</contrib>
<contrib contrib-type="author">
<name>
<surname>McCracken</surname>
<given-names>James T.</given-names>
</name>
<degrees>MD</degrees>
<aff id="A9">Department of Psychiatry and Biobehavioral Sciences, Semel Institute, David Geffen School of Medicine at UCLA, Los Angeles</aff>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Parr</surname>
<given-names>Jeremy R</given-names>
<prefix>Dr</prefix>
</name>
<degrees>MBChB</degrees>
<aff id="A10">Institute of Neuroscience, Newcastle University, UK</aff>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Santosh</surname>
<given-names>Paramala</given-names>
</name>
<degrees>PhD, FRCPsych</degrees>
<aff id="A11">Department of Child Psychiatry, Institute of Psychiatry, Psychology &amp; Neuroscience, King’s College London</aff>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wallace</surname>
<given-names>Simon</given-names>
</name>
<degrees>PhD</degrees>
<aff id="A12">AT-Autism, 20-22 Wenlock Road, London, N1 7GU</aff>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Murphy</surname>
<given-names>Declan G.</given-names>
<prefix>Prof.</prefix>
</name>
<degrees>FRCPsych</degrees>
<aff id="A13">The Sackler Centre and Forensic and Neurodevelopmental Science Behavioural and Developmental Psychiatry, Clinical Academic Group and NIHR-BRC for Mental Health at South London and Maudsley NHS Foundation Trust</aff>
</contrib>
</contrib-group>
<author-notes>
<fn fn-type="COI-statement" id="FN1">
<p id="P1">
<bold>Oliver D Howes</bold>
</p>
<p id="P2">Conflicts of Interest: Dr Howes has received investigator-initiated research funding from and/or participated in advisory/ speaker meetings organised by Astra-Zeneca, Autifony, BMS, Eli Lilly, Heptares, Jansenn, Lundbeck, Lyden-Delta, Otsuka, Servier, Sunovion, Rand and Roche.</p>
</fn>
<fn fn-type="COI-statement" id="FN2">
<p id="P3">
<bold>Maria Rogdaki</bold>
</p>
<p id="P4">Conflicts of Interest: None</p>
</fn>
<fn fn-type="COI-statement" id="FN3">
<p id="P5">
<bold>James L. Findon</bold>
</p>
<p id="P6">Conflicts of Interest: None</p>
</fn>
<fn fn-type="COI-statement" id="FN4">
<p id="P7">
<bold>Robert H. Wichers</bold>
</p>
<p id="P8">Conflicts of Interest: None</p>
</fn>
<fn fn-type="COI-statement" id="FN5">
<p id="P9">
<bold>Tony Charman</bold>
</p>
<p id="P10">Conflicts of Interest: None</p>
</fn>
<fn fn-type="COI-statement" id="FN6">
<p id="P11">
<bold>Bryan H. King</bold>
</p>
<p id="P12">Conflicts of Interest: None</p>
</fn>
<fn fn-type="COI-statement" id="FN7">
<p id="P13">
<bold>Eva Loth</bold>
</p>
<p id="P14">Conflicts of Interest: None</p>
<p id="P15">Note: I'm not a member of the BAP – see title?</p>
</fn>
<fn fn-type="COI-statement" id="FN8">
<p id="P16">
<bold>Gráinne M. McAlonan</bold>
</p>
<p id="P17">Conflicts of Interest: None</p>
</fn>
<fn fn-type="COI-statement" id="FN9">
<p id="P18">
<bold>James T. McCracken</bold>
</p>
<p id="P19">Conflicts of Interest: Alcobra Pharmaceuticals (DSMB honorarium), Psyadon Pharmaceuticals (clinical trial), AstraZeneca (study medication)</p>
</fn>
<fn fn-type="COI-statement" id="FN10">
<p id="P20">
<bold>Jeremy R Parr</bold>
</p>
<p id="P21">Conflicts of Interest: None</p>
</fn>
<fn fn-type="COI-statement" id="FN11">
<p id="P22">
<bold>Paramala Santosh</bold>
</p>
<p id="P23">Conflicts of Interest: Newron Pharmaceuticals (clinical trial).</p>
</fn>
<fn fn-type="COI-statement" id="FN12">
<p id="P24">
<bold>Simon Wallace</bold>
</p>
<p id="P25">Conflicts of Interest: None</p>
</fn>
<fn fn-type="COI-statement" id="FN13">
<p id="P26">
<bold>Declan G. Murphy</bold>
</p>
<p id="P27">Conflicts of Interest: None</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>2</day>
<month>2</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>14</day>
<month>12</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="ppub">
<month>1</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>08</day>
<month>2</month>
<year>2018</year>
</pub-date>
<volume>32</volume>
<issue>1</issue>
<fpage>3</fpage>
<lpage>29</lpage>
<!--elocation-id from pubmed: 10.1177/0269881117741766-->
<abstract>
<p id="P28">An expert review of the aetiology, assessment, and treatment of autism spectrum disorder (ASD), and recommendations for diagnosis, management and service provision was coordinated by the British Association for Psychopharmacology, and evidence graded.</p>
<p id="P29">The aetiology of ASD involves genetic and environmental contributions, and implicates a number of brain systems, in particular the gamma-aminobutyric acid (GABA), serotonergic and glutamatergic systems. The presentation of ASD varies widely and co-occurring health problems (in particular epilepsy, sleep disorders, anxiety, depression, attention deficit/hyperactivity disorder (ADHD), and irritability) are common. We did not recommend the routine use of any pharmacological treatment for the core symptoms of ASD. In children, melatonin may be useful to treat sleep problems, dopamine blockers for irritability, and methylphenidate, atomoxetine and guanfacine for ADHD. The evidence for use of medication in adults is limited and recommendations are largely based on extrapolations from studies in children and patients without ASD. We discuss the conditions for considering and evaluating a trial of medication treatment, when non-pharmacological interventions should be considered, and make recommendations on service delivery. Finally, we identify key gaps and limitations in the current evidence base and make recommendations for future research and the design of clinical trials.</p>
</abstract>
</article-meta>
</front>
</article>
</pmc-articleset>